Numerous preclinical studies implicate the decline in NAD⁺ signaling in developing aging- and obesity-associated metabolic disorders. Yoshino et al. (2021) now provide the clinical evidence that an NAD⁺ booster increases muscle insulin sensitivity in postmenopausal prediabetic women, validating the therapeutic promises of NAD⁺ boosters in humans.

中文翻译：

---

NAD+ 增强剂的治疗前景

许多临床前研究表明，NAD ⁺信号传导在发生衰老和肥胖相关的代谢疾病中的下降。吉野等人。（2021）现在提供临床证据表明NAD ⁺绝经后女性糖尿病前期助推器增加肌肉对胰岛素的敏感性，验证NAD的治疗承诺⁺助推器人类。